Pure Global AI
NCT06246227Recruitment Completed

ctDNA for Early Detection of Recurrence in Melanoma

The Value of Circulating Tumour DNA in Early Detection of Recurrence of Melanoma
Herlev and Gentofte HospitalClinicalTrials.gov
Verified
Study focus
Disease/Condition
Melanoma
Study type
Observational
Sponsor & location
Primary sponsor
Herlev and Gentofte Hospital
Location
Herlev, Denmark
Timeline & enrollment
Phase
N/A
Start date
Jul 01, 2019
End date
Jan 01, 2028
Enrollment
467 participants
Primary outcome

Sensitivity of ctDNA for detection of metastatic disease,Specificity of ctDNA for detection of metastatic disease

Summary

This study examines circulating tumor DNA (ctDNA) as a biomarker for early detection of
 recurrence in high-risk patients, following treatment of primary melanoma. The hypothesis is
 that ctDNA can provide accurate detection of recurrence or metastasis, at the time of or
 earlier than current methods, leading to improved management and hopefully prognosis, based
 on earlier detection.

ICD-10 classifications
Malignant melanoma of skinMelanoma in situ, unspecifiedMelanoma in situMelanoma and other malignant neoplasms of skinMalignant neoplasm: Malignant melanoma of skin, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06246227
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06246227 through Pure Global AI's free database. This phase not specified trial is sponsored by Herlev and Gentofte Hospital and is currently Recruitment Completed. The study focuses on Melanoma. Target enrollment is 467 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.